A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications

A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications

Mett et al. describe development of GP532, a substantially deimmunized derivative of Toll-like receptor 5 (TLR5) agonist entolimod. GP532 has mutations eliminating key B- and T-cell epitopes and an inflammasome-activating domain yet remains a potent NF-κB activator with biological effects similar to...

Full description

Bibliographic Details
Main Authors: Vadim Mett, Oleg V. Kurnasov, Ivan A. Bespalov, Ivan Molodtsov, Craig M. Brackett, Lyudmila G. Burdelya, Andrei A. Purmal, Anatoli S. Gleiberman, Ilia A. Toshkov, Catherine A. Burkhart, Yakov N. Kogan, Ekaterina L. Andrianova, Andrei V. Gudkov, Andrei L. Osterman
Format: Article
Language:English
Published: Nature Publishing Group 2021-04-01
Series:Communications Biology
Online Access:https://doi.org/10.1038/s42003-021-01978-6

Internet

https://doi.org/10.1038/s42003-021-01978-6

Similar Items